AnaptysBio, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California. It focuses on the development of antibody therapeutics targeting immune-mediated inflammatory diseases and cancer.
The company’s platform technology enables the rapid discovery and optimization of fully human antibodies using its proprietary SHM-XEL™ system.
AnaptysBio has a pipeline of wholly-owned programs, including ANB032 for atopic dermatitis, ANB033 for celiac disease, and ANB091 for moderate-to-severe psoriasis.
Also known as Anaptys Royalty Co.
FDA sets PDUFA Feb 2027 for Jemperli’s supplemental filing based on AZUR‑1 data showing sustained 12‑month complete responses, potentially avoiding chemo, radiation and surgery.
Interim phase II results met primary endpoint (cCR12); trial suggests some patients may avoid chemo, radiation and surgery. Data to be shared with regulators including for US accelerated review.
